癌症是一类广泛的疾病，当异常细胞无限制地生长，侵袭周围组织和/或扩散到其他器官时，可以影响身体的几乎所有器官或组织。Dabrafenib适用于治疗晚期非小细胞肺癌的成年患者。在本研究中，我们提出了两种新开发的用于检测抗癌药物Dabrafenib（DRF）在其真实和药品产品中的发荧光探针，使用从鼠尾草叶提取物中生态合成的氧化铜纳米颗粒（CuONPs）和铜螯合物。第一个系统基于CuONPs的特殊光学性质对发光检测的增强作用，而第二个系统则通过形成铜电荷转移复合物起作用。进行了各种光谱和显微研究来确认环境合成的CuONPs。这两个系统的荧光检测分别在λex 350和λem 432 nm处进行测量。结果显示DRF-CuONPs-SDS和DRF-Cu-SDS络合物的线性浓度范围分别确定为1.0-500 ng mL- 1和1.0-200 ng mL- 1。回归方程为FI = 1.8088x + 21.418（r = 0.9997）和FI = 2.7536x + 163.37（r = 0.9989）。前述荧光系统的较低检测和定量限为0.4和0.8 ng mL- 1和1.0 ng mL- 1。结果还显示，使用DRF-CuONPs-SDS和DRF-Cu(NO3)2-SDS系统进行的逐日DRF测定的百分比分别为0.17％和0.54％。然而，上述系统的日间间测结果为0.27％和0.65％。前述两个系统在DRF研究中被有效地使用，百分比回收率分别为99.66±0.42％和99.42±0.56％。在制药配方中使用的饱和脂肪酸镁、二氧化钛、红铁氧化物和二氧化硅以及各种常见阳离子、氨基酸和糖对化合物的检测没有影响。© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Cancer is a broad category of disease that can affect virtually any organ or tissue in the body when abnormal cells grow uncontrollably, invade surrounding tissue, and/or spread to other organs. Dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer. In the present study, two newly developed spectrofluorimetric probes for the detection of the anticancer drug Dabrafenib (DRF) in its authentic and pharmaceutical products using an ecologically synthesized copper oxide nanoparticle (CuONPs) from Salvia officinalis leaf extract and a copper chelate complex are presented. The first system is based on the influence of the particular optical properties of CuONPs on the enhancement of fluorescence detection. The second system, on the other hand, acts through the formation of a copper charge transfer complex. Various spectroscopic and microscopic studies were performed to confirm the environmentally synthesized CuONPs. The fluorescence detections in the two systems were measured at λex 350 and λem of 432 nm. The results showed the linear concentration ranges for the DRF-CuONPs-SDS and DRF-Cu-SDS complexes were determined to be 1.0-500 ng mL- 1 and 1.0-200 ng mL- 1, respectively. FI = 1.8088x + 21.418 (r = 0.9997) and FI = 2.7536x + 163.37 (r = 0.9989) were the regression equations. The lower detection and quantification limits for the aforementioned fluorescent systems were determined to be 0.4 and 0.8 ng mL- 1 and 1.0 ng mL- 1, respectively. The results also showed that intra-day DRF assays using DRF-CuONPs-SDS and DRF-Cu(NO3)2-SDS systems yielded 0.17% and 0.54%, respectively. However, the inter-day assay results for the above systems were 0.27% and 0.65%, respectively. The aforementioned two systems were effectively used in the study of DRF with excellent percent recoveries of 99.66 ± 0.42% and 99.42 ± 0.56%, respectively. Excipients such as magnesium stearate, titanium dioxide, red iron oxide, and silicon dioxide used in pharmaceutical formulations, as well as various common cations, amino acids, and sugars, had no effect on the detection of compound.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.